Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide R-CHOP vs R-CHOP in Newly Diagnosed DLBCL
NCT01856192Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2013
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Started Aug 2013; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01856192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856192.